Orvosi Hetilap
Volume/Issue:
Volume 151: Issue 19
New perspective in immunotherapy: local imiquimod treatment
Authors: Lajos Kemény and Nikoletta Nagy 1
View More View Less
  • 1 Szegedi Tudományegyetem, Általános Orvostudományi Kar Bőrgyógyászati és Allergológiai Klinika Szeged Korányi fasor 6. 6720
  • 2 Magyar Tudományos Akadémia–Szegedi Tudományegyetem Dermatológiai Kutatócsoport Szeged
DOI:
https://doi.org/10.1556/oh.2010.28866
Page Count:
774–783
Publication Date:
01 May 2010
Online Publication Date:
28 Apr 2010
Article Category:
Research Article
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00
Purchase Online Subscription

  • Purchase article

    USD  $25.00

  • 1 year subscription (Individual Only)

    USD  $1,070.00

Az imikimod, az imidazol-kinolin-aminok családjába tartozó, kis, szintetikus, nukleotidszerű molekula. Ismert immunválasz-módosító, vírusellenes és tumorellenes hatása, amelyet a Toll-like receptorok (TLR7 és TLR8) közvetítenek. Az imikimod főként a TLR7-et kifejező plazmacitoid dendritikus sejteket és a Langerhans-sejteket célozza meg, és csak másodlagosan vesz részt egyéb gyulladásos sejtek aktiválásában. A TLR7 stimulációjakor indukálódó jelátviteli mechanizmusok mind a veleszületett, mind a szerzett immunrendszert aktiválják, különös tekintettel a sejt által közvetített immunreakciókra. Az 5%-os imikimodkrém (Aldara, MEDA Pharma) lokális alkalmazása hatékonynak bizonyult az aktinikus keratosisok, a superficialis basaliomák és a külső nemi szerveken és perianalisan elhelyezkedő condylomák kezelésében. Az imikimod különösen alkalmas kiterjedt, látszólag tünetmentes, de daganatsejteket tartalmazó mezők („field cancerization”) kezelésére. A beteg által alkalmazott otthoni kezelés kiváló kozmetikai eredményt ad. Irodalmi adatok utalnak továbbá az imikimod hatékonyságára nodularis basalioma és egyéb, nem melanomatípusú bőrdaganat kezelésében. Az imikimod lokális alkalmazása jól tolerálható, a krém az alkalmazás helyén enyhe vagy közepesen súlyos gyulladásos reakciót okozhat. Ez a dolgozat átfogó képet ad az imikimod alkalmazásával kapcsolatos eddigi tapasztalatokról és a potenciális jövőbeli felhasználási lehetőségekről.

  • Berg, D., Otley, C. C.: Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. J. Am. Acad. Dermatol., 2002, 47 , 1–17.

    Otley C. C. , 'Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management ' (2002 ) 47 J. Am. Acad. Dermatol. : 1 -17.

    • Search Google Scholar

  • Euvrard, S., Kanitakis, J., Claudy, A.: Skin cancers after organ transplantation. N. Engl. J. Med., 2003, 348 , 1681–1691.

    Claudy A. , 'Skin cancers after organ transplantation ' (2003 ) 348 N. Engl. J. Med. : 1681 -1691.

    • Search Google Scholar

  • Sheil, A. G., Disney, A. P., Mathew, T. G. és mtsai: Malignancy following renal transplantation. Transplant. Proc., 1992, 24 , 1946–1947.

    Mathew T. G. , 'Malignancy following renal transplantation ' (1992 ) 24 Transplant. Proc. : 1946 -1947.

    • Search Google Scholar

  • Akira, S., Hemmi, H.: Recognition of pathogen-associated molecular patterns by TLR family. Immunol. Lett., 2003, 85 , 85–95.

    Hemmi H. , 'Recognition of pathogen-associated molecular patterns by TLR family ' (2003 ) 85 Immunol. Lett. : 85 -95.

    • Search Google Scholar

  • Diebold, S. S., Kaisho, T., Hemmi, H. és mtsai: Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science, 2004, 303 , 1529–1531.

    Hemmi H. , 'Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA ' (2004 ) 303 Science : 1529 -1531.

    • Search Google Scholar

  • Heil, F., Hemmi, H., Hochrein, H. és mtsai: Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science, 2004, 303 , 1526–1529.

    Hochrein H. , 'Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8 ' (2004 ) 303 Science : 1526 -1529.

    • Search Google Scholar

  • Akira, S., Takeda, K.: Toll-like receptor signalling. Nat. Rev. Immunol., 2004, 4 , 499–511.

    Takeda K. , 'Toll-like receptor signalling ' (2004 ) 4 Nat. Rev. Immunol. : 499 -511.

  • Medzhitov, R., Preston-Hurlburt, P., Janeway, C. A.: A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature, 1997, 388 , 394–397.

    Janeway C. A. , 'A human homologue of the Drosophila Toll protein signals activation of adaptive immunity ' (1997 ) 388 Nature : 394 -397.

    • Search Google Scholar

  • Barnetson, R. S., Satchell, A., Zhuang, L. és mtsai: Imiquimod induced regression of clinically diagnosed superficial basal cell carcinoma is associated with early infiltration by CD4 T cells and dendritic cells. Clin. Exp. Dermatol., 2004, 29 , 639–643.

    Zhuang L. , 'Imiquimod induced regression of clinically diagnosed superficial basal cell carcinoma is associated with early infiltration by CD4 T cells and dendritic cells ' (2004 ) 29 Clin. Exp. Dermatol. : 639 -643.

    • Search Google Scholar

  • Michalopoulos, P., Yawalkar, N., Bronnimann, M. és mtsai: Characterization of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod. Br. J. Dermatol., 2004, 151 , 903–906.

    Bronnimann M. , 'Characterization of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod ' (2004 ) 151 Br. J. Dermatol. : 903 -906.

    • Search Google Scholar

  • Smith, K. J., Hamza, S., Skelton, H.: Topical imidazoquinoline therapy of cutaneous squamous cell carcinoma polarizes lymphoid and monocyte/macrophage populations to a Th1 and M1 cytokine pattern. Clin. Exp. Dermatol., 2004, 29 , 505–512.

    Skelton H. , 'Topical imidazoquinoline therapy of cutaneous squamous cell carcinoma polarizes lymphoid and monocyte/macrophage populations to a Th1 and M1 cytokine pattern ' (2004 ) 29 Clin. Exp. Dermatol. : 505 -512.

    • Search Google Scholar

  • Peng, G., Guo, Z., Kiniwa, Y. és mtsai: Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science, 2005, 309 , 1380–1384.

    Kiniwa Y. , 'Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function ' (2005 ) 309 Science : 1380 -1384.

    • Search Google Scholar

  • Schon, M., Bong, A. B., Drewniok, C. és mtsai: Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J. Natl. Cancer. Inst., 2005, 95 , 1138–1149.

    Drewniok C. , 'Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod ' (2005 ) 95 J. Natl. Cancer. Inst. : 1138 -1149.

    • Search Google Scholar

  • Schon, M. P., Schon, M., Klotz, K. N.: The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J. Invest. Dermatol., 2006, 126 , 1338–1347.

    Klotz K. N. , 'The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion ' (2006 ) 126 J. Invest. Dermatol. : 1338 -1347.

    • Search Google Scholar

  • Meyer, T., Nindl, I., Schmook, T. és mtsai: Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures. Br. J. Dermatol., 2003, 66 , 9–14.

    Schmook T. , 'Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures ' (2003 ) 66 Br. J. Dermatol. : 9 -14.

    • Search Google Scholar

  • Li, V. W., Li, W. W., Talcott, K. E. és mtsai: Imiquimod as an antiangiogenic agent. J. Drugs Dermatol., 2005, 4 , 708–717.

    Talcott K. E. , 'Imiquimod as an antiangiogenic agent ' (2005 ) 4 J. Drugs Dermatol. : 708 -717.

    • Search Google Scholar

  • Stary, G., Bangert, C., Tauber, M. és mtsai: Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J. Exp. Med., 2007, 204 , 1441–1451.

    Tauber M. , 'Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells ' (2007 ) 204 J. Exp. Med. : 1441 -1451.

    • Search Google Scholar

  • Wagstaff, A. J., Perry, C. M.: Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions. Drugs, 2007, 67 , 2187–2210.

    Perry C. M. , 'Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions ' (2007 ) 67 Drugs : 2187 -2210.

    • Search Google Scholar

  • Harrison, L. I., Skinner, S. L., Marbury, T. C. és mtsai: Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms. Arch. Dermatol. Res., 2004, 296 , 6–11.

    Marbury T. C. , 'Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms ' (2004 ) 296 Arch. Dermatol. Res. : 6 -11.

    • Search Google Scholar

  • Ackerman, A. B.: Solar keratosis is squamous cell carcinoma. Arch. Dermatol., 2003, 139 , 1216–1217.

    Ackerman A. B. , 'Solar keratosis is squamous cell carcinoma ' (2003 ) 139 Arch. Dermatol. : 1216 -1217.

    • Search Google Scholar

  • Memon, A. A., Tomenson, J. A., Bothwell, J. és mtsai: Prevalence of solar damage and actinic keratosis in a Merseyside population. Br. J. Dermatol., 2000, 142 , 1154–1159.

    Bothwell J. , 'Prevalence of solar damage and actinic keratosis in a Merseyside population ' (2000 ) 142 Br. J. Dermatol. : 1154 -1159.

    • Search Google Scholar

  • Braakhuis, B. J., Tabor, M. P., Kummer, J. A. és mtsai: A genetic explanation of Slaughter’s concept of field cancerization: evidence and clinical implications. Cancer Res., 2003, 63 , 1727–1730.

    Kummer J. A. , 'A genetic explanation of Slaughter’s concept of field cancerization: evidence and clinical implications ' (2003 ) 63 Cancer Res. : 1727 -1730.

    • Search Google Scholar

  • Glogau, R. G.: The risk of progression to invasive disease. J. Am. Acad. Dermatol., 2000, 42 , 23–24.

    Glogau R. G. , 'The risk of progression to invasive disease ' (2000 ) 42 J. Am. Acad. Dermatol. : 23 -24.

    • Search Google Scholar

  • Stockfleth, E., Ulrich, C., Meyer, T. és mtsai: Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment. Recent Results Cancer Res., 2003, 160 , 251–258.

    Meyer T. , 'Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment ' (2003 ) 160 Recent Results Cancer Res. : 251 -258.

    • Search Google Scholar

  • Ulrich, C., Christophers, E., Sterry, W. és mtsai: Skin diseases in organ transplant patients. Hautarzt, 2002, 53 , 524–533.

    Sterry W. , 'Skin diseases in organ transplant patients ' (2002 ) 53 Hautarzt : 524 -533.

  • Lebwohl, M., Dinehart, S., Whiting, D. és mtsai: Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J. Am. Acad. Dermatol., 2004, 50 , 714–721.

    Whiting D. , 'Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials ' (2004 ) 50 J. Am. Acad. Dermatol. : 714 -721.

    • Search Google Scholar

  • Stockfleth, E., Meyer, T., Benninghoff, B. és mtsai: A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch. Dermatol., 2002, 138 , 1498–1502.

    Benninghoff B. , 'A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses ' (2002 ) 138 Arch. Dermatol. : 1498 -1502.

    • Search Google Scholar

  • Stockfleth, E., Christophers, E., Benninghoff, B. és mtsai: Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study. Arch. Dermatol., 2004, 140 , 1542.

    Benninghoff B. , 'Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study ' (2004 ) 140 Arch. Dermatol. : 1542 -.

    • Search Google Scholar

  • Szeimies, R. M., Gerritsen, M. J., Gupta, G. és mtsai: Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J. Am. Acad. Dermatol., 2004, 51 , 547–555.

    Gupta G. , 'Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology ' (2004 ) 51 J. Am. Acad. Dermatol. : 547 -555.

    • Search Google Scholar

  • Korman, N., Moy, R., Ling, M. és mtsai: Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch. Dermatol., 2005, 141 , 467–473.

    Ling M. , 'Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials ' (2005 ) 141 Arch. Dermatol. : 467 -473.

    • Search Google Scholar

  • Alomar, A., Bichel, J., McRae, S.: Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br. J. Dermatol., 2007, 157 , 133–141.

    McRae S. , 'Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head ' (2007 ) 157 Br. J. Dermatol. : 133 -141.

    • Search Google Scholar

  • Hadley, G., Derry, S., Moore, R. A.: Imiquimod for actinic keratosis: systematic review and meta-analysis. J. Invest. Dermatol., 2006, 126 , 1251–1255.

    Moore R. A. , 'Imiquimod for actinic keratosis: systematic review and meta-analysis ' (2006 ) 126 J. Invest. Dermatol. : 1251 -1255.

    • Search Google Scholar

  • Ulrich, C., Bichel, J., Euvrard, S. és mtsai: Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br. J. Dermatol., 2007, 2 , 25–31.

    Euvrard S. , 'Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients ' (2007 ) 2 Br. J. Dermatol. : 25 -31.

    • Search Google Scholar

  • Kowalzick, L., Rogozinski, T., Wimheuer, R. és mtsai: Intralesional recombinant interferon beta-1a in the treatment of basal cell carcinoma: results of an open-label multicentre study. Eur. J. Dermatol., 2002, 12 , 558–561.

    Wimheuer R. , 'Intralesional recombinant interferon beta-1a in the treatment of basal cell carcinoma: results of an open-label multicentre study ' (2002 ) 12 Eur. J. Dermatol. : 558 -561.

    • Search Google Scholar

  • Beutner, K. R., Geisse, J. K., Helman, D. és mtsai: Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J. Am. Acad. Dermatol., 1999, 41 , 1002–1007.

    Helman D. , 'Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream ' (1999 ) 41 J. Am. Acad. Dermatol. : 1002 -1007.

    • Search Google Scholar

  • Marks, R., Gebauer, K., Shumack, S. és mtsai: Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J. Am. Acad. Dermatol., 2001, 44 , 807–813.

    Shumack S. , 'Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial ' (2001 ) 44 J. Am. Acad. Dermatol. : 807 -813.

    • Search Google Scholar

  • Sterry, W., Ruzicka, T., Herrera, E. és mtsai: Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br. J. Dermatol., 2002, 147 , 1227–1236.

    Herrera E. , 'Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion ' (2002 ) 147 Br. J. Dermatol. : 1227 -1236.

    • Search Google Scholar

  • Shumack, S., Robinson, J., Kossard, S. és mtsai: Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch. Dermatol., 2002, 138 , 1165–1171.

    Kossard S. , 'Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens ' (2002 ) 138 Arch. Dermatol. : 1165 -1171.

    • Search Google Scholar

  • Geisse, J., Caro, I., Lindholm, J. és mtsai: Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J. Am. Acad. Dermatol., 2004, 50 , 722–733.

    Lindholm J. , 'Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies ' (2004 ) 50 J. Am. Acad. Dermatol. : 722 -733.

    • Search Google Scholar

  • Ezughah, F. I., Affleck, A. G., Evans, A. és mtsai: Confirmation of histological clearance of superficial basal cell carcinoma with multiple serial sectioning and Mohs’ micrographic surgery following treatment with imiquimod 5% cream. J. Dermatol. Treat., 2008, 19 , 156–158.

    Evans A. , 'Confirmation of histological clearance of superficial basal cell carcinoma with multiple serial sectioning and Mohs’ micrographic surgery following treatment with imiquimod 5% cream ' (2008 ) 19 J. Dermatol. Treat. : 156 -158.

    • Search Google Scholar

  • Neville, J. A., Williford, P. M., Jorizzo, J. L.: Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage. J. Drugs Dermatol., 2007, 6 , 910–914.

    Jorizzo J. L. , 'Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage ' (2007 ) 6 J. Drugs Dermatol. : 910 -914.

    • Search Google Scholar

  • Spencer, J. M.: Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma. Dermatol. Surg., 2006, 32 , 63–69.

    Spencer J. M. , 'Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma ' (2006 ) 32 Dermatol. Surg. : 63 -69.

    • Search Google Scholar

  • Tyring, S. K., Arany, I., Stanley, M. A. és mtsai: A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J. Infect. Dis., 1998, 178 , 551–555.

    Stanley M. A. , 'A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod ' (1998 ) 178 J. Infect. Dis. : 551 -555.

    • Search Google Scholar

  • Beutner, K. R., Spruance, S. L., Hougham, A. J. és mtsai: Treatment of genital warts with an immune-response modifier (imiquimod). J. Am. Acad. Dermatol., 1998, 38 , 230–239.

    Hougham A. J. , 'Treatment of genital warts with an immune-response modifier (imiquimod) ' (1998 ) 38 J. Am. Acad. Dermatol. : 230 -239.

    • Search Google Scholar

  • Schöfer, H., Van Ophoven, A., Henke, U. és mtsai: Randomized, comparative trial on the sustained efficacy of topical imiquimod 5% cream versus conventional ablative methods in external anogenital warts. Eur. J. Dermatol., 2006, 16 , 642–648.

    Henke U. , 'Randomized, comparative trial on the sustained efficacy of topical imiquimod 5% cream versus conventional ablative methods in external anogenital warts ' (2006 ) 16 Eur. J. Dermatol. : 642 -648.

    • Search Google Scholar

  • Garland, S. M., Sellors, J. W., Wikstrom, A. és mtsai: Imiquimod 5% cream is a safe and effective self-applied treatment for anogenital warts – results of an open-label, multicentre Phase IIIB trial. Int. J. STD. AIDS, 2001, 12 , 722–729.

    Wikstrom A. , 'Imiquimod 5% cream is a safe and effective self-applied treatment for anogenital warts – results of an open-label, multicentre Phase IIIB trial ' (2001 ) 12 Int. J. STD. AIDS : 722 -729.

    • Search Google Scholar

  • Mackenzie-Wood, A., Kossard, S., de Launey, J. és mtsai: Imiquimod 5% cream in the treatment of Bowen’s disease. J. Am. Acad. Dermatol., 2001, 44 , 462–470.

    Launey J. , 'Imiquimod 5% cream in the treatment of Bowen’s disease ' (2001 ) 44 J. Am. Acad. Dermatol. : 462 -470.

    • Search Google Scholar

  • Schroeder, T. L., Sengelmann, R. D.: Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% cream. J. Am. Acad. Dermatol., 2002, 46 , 545–548.

    Sengelmann R. D. , 'Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% cream ' (2002 ) 46 J. Am. Acad. Dermatol. : 545 -548.

    • Search Google Scholar

  • Orengo, I., Rosen, T., Guill, C. K.: Treatment of squamous cell carcinoma in situ of the penis with 5% imiquimod cream: a case report. J. Am. Acad. Dermatol., 2002, 47 , S225–S228.

    Guill C. K. , 'Treatment of squamous cell carcinoma in situ of the penis with 5% imiquimod cream: a case report ' (2002 ) 47 J. Am. Acad. Dermatol. : S225 -S228.

    • Search Google Scholar

  • Novak, N., Yu, C. F., Bieber, T. és mtsai: Toll-like receptor 7 agonists and skin. Drug News Perspect., 2008, 21 , 158–165.

    Bieber T. , 'Toll-like receptor 7 agonists and skin ' (2008 ) 21 Drug News Perspect. : 158 -165.

    • Search Google Scholar
Cover Orvosi Hetilap
Orvosi Hetilap
Print ISSN:
0030-6002
Online ISSN:
1788-6120
Keywords:
imikimod; immunválasz-módosító; aktinikus keratosis; basalioma; condyloma; imiquimod; immune response modifier; actinic keratosis; basal cell carcinoma; condyloma

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Aug 2020 33 0 0
Sep 2020 33 0 1
Oct 2020 20 4 5
Nov 2020 28 0 0
Dec 2020 43 1 2
Jan 2021 36 1 1
Feb 2021 0 0 0